Therapeutic response of ACTH-dependent ectopic Cushing's syndrome to low doses of osilodrostat

#3764

Introduction: Cushing's disease (CD) is the main cause of ACTH-dependent Cushing's syndrome (ACTH-CS). In 5–15% of cases, ACTH/CRH production is ectopic and is caused by neuroendocrine tumors of the lung, thymus, or pancreas, medullary thyroid carcinoma, and pheochromocytoma. Diagnostic imaging can locate the primary tumor; however, between 8-22% the cause is unknown. The FDA approved Osilodrostat for the treatment of inoperable or refractory CD, its use in high doses in patients with ectopic CS has been reported.

Aim(s): To report the therapeutic response to Osilodrostat ACTH-CS.

Materials and methods: A retrospective review was made.

Conference:

Presenting Author:

Authors: González Devia D, Florez-Romero A, Rojas-Camacho J, Herrera Almario G, Jimenez Hakim E,

Keywords: ACTH-dependent Cushing's syndrome, Osilodrostat, Adrenal steroidogenesis inhibitors, Ectopic ACTH Cushing´s syndrome,